Method for improving cardiovascular risk profile of cox inhibitors
OwnerAllison B. Reiss, Steven Carsonsinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerAllison B. Reiss, Steven Carsonsinventors
Estimating the term…
A method of reducing the increased risk of cardiovascular events attendant with the use of COX or selective COX-2 inhibitors including restoring disrupted cholesterol metabolic function engendered by the use of the COX or selective COX-2 inhibitors and reducing the production of foam cells caused thereby. The disrupted cholesterol metabolic function is restored and the production of foam cells is reduced by the step of administering an adenosine A2A receptor agonist having a threshold level of activity of 0.1 μM to a patient using the COX or COX-2 inhibitor. The adenosine A2A receptor agonist is administered orally in amounts sufficient to saturate the A2A receptor and at time intervals sufficient to maintain the restored cholesterol metabolic function.
A method of reducing the increased risk of adverse atherosclerotic cardiovascular and cerebrovascular conditions in a human resulting from the use by the human of a COX or selective COX-2 inhibitor, the method comprising:
A pharmaceutical composition comprising a pharmaceutically acceptable selective COX-2 inhibitor and a pharmaceutically acceptable A2A receptor agonist, with the A2A receptor agonist being present in an amount sufficient to restore cholesterol metabolic function disrupted by the selective COX-2 inhibitor.
A method of reducing the risk or myocardial infarction and stroke in a human to whom COX or selective COX-2 inhibitors are administered, comprising administering to said human an adenosine A2A receptor antagonist.
A method of ameliorating atherogenesis in a mammal including a human, comprising:
A pharmaceutical composition comprising:
A method of reducing effect in a mammal resulting from the use by the mamal of a COX or selective COX-2 inhibitor which disrupts a normal cholesterol metabolic function;
A method of reducing the increased risk of adverse atherosclerotic cardiovascular and cerebrovascular conditions in a human resulting from the use by the human of a COX or selective COX-2 inhibitor, the method comprising restoring disrupted cholesterol metabolic function engendered by COX or selective COX-2 inhibitor.
Dependencies are inferred from the claim text.